Antonio Llombart-Cussac

Summary

Affiliation: Hospital Universitari Arnau de Vilanova
Country: Spain

Publications

  1. ncbi Pemetrexed in patients with locally advanced or metastatic breast cancer who had received previous anthracycline and taxane treatment: phase II study
    Antonio Llombart-Cussac
    Instituto Valenciano de Oncologia, Valencia, Spain
    Clin Breast Cancer 7:380-5. 2006
  2. doi Improving decision-making in early breast cancer: who to treat and how?
    Antonio Llombart-Cussac
    Medical Oncology Service, Hospital Universitario Arnau Vilanova, Av Alcalde Rovira Roure 80, 25198, Lleida, Spain
    Breast Cancer Res Treat 112:15-24. 2008
  3. doi Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial
    Antonio Llombart-Cussac
    Medical Oncology Service, Biomedical Research Institute, Arnau de Vilanova University Hospital, Lleida, Spain
    Cancer 118:241-7. 2012
  4. ncbi A randomized, double-blind, phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer
    Antonio Llombart-Cussac
    Hospital Universitario Arnau Vilanova, Lleida, Spain
    Clin Cancer Res 13:3652-9. 2007
  5. doi Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[+] operable breast cancer
    Antonio Llombart-Cussac
    Instituto Valenciano de Oncologia, Valencia, Spain
    Clin Transl Oncol 14:125-31. 2012
  6. doi Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway
    Andree Yeramian
    Pathology Group, Department of Pathology and Molecular Genetics, Hospital Universitari Arnau de Vilanova, University of Lleida, IRB Lleida, Lleida, Spain
    Int J Cancer 130:967-78. 2012
  7. pmc A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole
    Zaida Garcia-Casado
    Laboratory of Molecular Biology, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain
    BMC Cancer 10:36. 2010
  8. doi Combinatorial therapy using dovitinib and ICI182.780 (fulvestrant) blocks tumoral activity of endometrial cancer cells
    Nuria Eritja
    Authors Affiliations Oncologic Pathology Group, Dept de Ciències Mèdiques Bàsiques, University of Lleida, Department of Pathology and Molecular Genetics, Hospital Universitari Arnau de Vilanova, Institut de Recerca Biomedica de Lleida, IRBLLEIDA, Lleida and Servicio de Oncología Médica, Hospital Arnau de Vilanova, Valencia, Spain
    Mol Cancer Ther 13:776-87. 2014
  9. doi Antioxidants block proteasome inhibitor function in endometrial carcinoma cells
    David Llobet
    Oncologic Pathology Group, Biomedical Research Institute, Lleida, Spain
    Anticancer Drugs 19:115-24. 2008
  10. ncbi Novel biomarkers in primary breast core biopsies to predict poor response to neoadjuvant chemotherapy and appearance of metastases
    Anna Novell
    Department of Medical Oncology, Hospital Universitari Arnau de Vilanova Universitat de Lleida, IRBLLEIDA, Lleida, Spain
    Histol Histopathol . 2016

Collaborators

Detail Information

Publications16

  1. ncbi Pemetrexed in patients with locally advanced or metastatic breast cancer who had received previous anthracycline and taxane treatment: phase II study
    Antonio Llombart-Cussac
    Instituto Valenciano de Oncologia, Valencia, Spain
    Clin Breast Cancer 7:380-5. 2006
    ..The objective of this study was to assess the efficacy and safety of pemetrexed in pretreated patients with advanced-stage breast cancer...
  2. doi Improving decision-making in early breast cancer: who to treat and how?
    Antonio Llombart-Cussac
    Medical Oncology Service, Hospital Universitario Arnau Vilanova, Av Alcalde Rovira Roure 80, 25198, Lleida, Spain
    Breast Cancer Res Treat 112:15-24. 2008
    ..This article reviews the latest advances in treatment for early breast cancer, and explores how research and clinical practice are evolving to improve therapies and treatment decision-making, allowing physicians to optimize patient care...
  3. doi Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial
    Antonio Llombart-Cussac
    Medical Oncology Service, Biomedical Research Institute, Arnau de Vilanova University Hospital, Lleida, Spain
    Cancer 118:241-7. 2012
    ..In the current study, the authors formally evaluated the activity of anastrozole and exemestane in postmenopausal women with hormone-responsive, advanced breast cancer...
  4. ncbi A randomized, double-blind, phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer
    Antonio Llombart-Cussac
    Hospital Universitario Arnau Vilanova, Lleida, Spain
    Clin Cancer Res 13:3652-9. 2007
    ..A secondary objective was to identify molecular biomarkers correlating with response and toxicity...
  5. doi Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[+] operable breast cancer
    Antonio Llombart-Cussac
    Instituto Valenciano de Oncologia, Valencia, Spain
    Clin Transl Oncol 14:125-31. 2012
    ..However, the optimum duration of endocrine PST remains uncertain...
  6. doi Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway
    Andree Yeramian
    Pathology Group, Department of Pathology and Molecular Genetics, Hospital Universitari Arnau de Vilanova, University of Lleida, IRB Lleida, Lleida, Spain
    Int J Cancer 130:967-78. 2012
    ..Altogether, our results suggest that melanoma cells harboring an activated RTK may be clinically responsive to pharmacologic RTK inhibition by Sunitinib, and a strategy combining Sunitinib and Bortezomib, may provide therapeutic benefit...
  7. pmc A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole
    Zaida Garcia-Casado
    Laboratory of Molecular Biology, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain
    BMC Cancer 10:36. 2010
    ..We evaluate a series of polymorphisms of CYP19A1 and their effect on response to neoadjuvant letrozole in early BC...
  8. doi Combinatorial therapy using dovitinib and ICI182.780 (fulvestrant) blocks tumoral activity of endometrial cancer cells
    Nuria Eritja
    Authors Affiliations Oncologic Pathology Group, Dept de Ciències Mèdiques Bàsiques, University of Lleida, Department of Pathology and Molecular Genetics, Hospital Universitari Arnau de Vilanova, Institut de Recerca Biomedica de Lleida, IRBLLEIDA, Lleida and Servicio de Oncología Médica, Hospital Arnau de Vilanova, Valencia, Spain
    Mol Cancer Ther 13:776-87. 2014
    ..These findings suggest that combinatory therapies using dovitinib plus ICI182.780 treatment can be truly effective in patients with endometrial carcinomas carrying FGFR2 mutations...
  9. doi Antioxidants block proteasome inhibitor function in endometrial carcinoma cells
    David Llobet
    Oncologic Pathology Group, Biomedical Research Institute, Lleida, Spain
    Anticancer Drugs 19:115-24. 2008
    ..Until now, all the antioxidants that blocked proteasome inhibitor-induced cell death also blocked the proteasome inhibitor mechanism of action...
  10. ncbi Novel biomarkers in primary breast core biopsies to predict poor response to neoadjuvant chemotherapy and appearance of metastases
    Anna Novell
    Department of Medical Oncology, Hospital Universitari Arnau de Vilanova Universitat de Lleida, IRBLLEIDA, Lleida, Spain
    Histol Histopathol . 2016
    ..In conclusion, finding biomarkers of chemoresitance (ypTNM II-III) and metastases can become a stepping stone for future studies that will need to be assessed in a bigger scale...
  11. ncbi Targeted therapies in gynecologic cancers and melanoma
    Eugenia Ortega
    Department of Medical Oncology, Dermatology, and Pathology, Hospital Universitari Arnau de Vilanova, University of Lleida IRB Lleida, Lleida, Spain
    Semin Diagn Pathol 25:262-73. 2008
    ..The most promising signaling pathways to be targeted for therapies in these tumors are the tyrosine kinase receptor (EGFR, HER2, c-KIT), the RAS/B-RAF/MAPK, the PI3K-mTOR, and apoptosis signaling pathways...
  12. ncbi HER2 amplification in recurrent breast cancer following breast-conserving therapy correlates with distant metastasis and poor survival
    Jose A López-Guerrero
    Unit of Molecular Biology, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain
    Int J Cancer 118:1743-9. 2006
    ..00008) and for survival (HR = 4.22; p = 0.004). In conclusion, HER2 amplification constitutes an independent poor prognostic factor for the MFI and OS in patients with recurrent breast cancer. The clinical implications are discussed...
  13. doi CtIP silencing as a novel mechanism of tamoxifen resistance in breast cancer
    Minhao Wu
    Department of Carcinogenesis, The University of Texas M D Anderson Cancer Center, Science Park Research Division, 1808 Park Road 1C, P O Box 389, Smithville, TX 78957, USA
    Mol Cancer Res 5:1285-95. 2007
    ....
  14. ncbi High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective study
    Ramon Colomer
    M D Anderson Cancer Center Spain, Madrid, Spain
    Cancer 110:2178-85. 2007
    ..In this specifically designed, prospective study, the authors addressed the predictive value of circulating levels of the extracellular domain (ECD) of HER2 in patients with metastatic breast cancer who were treated with letrozole...
  15. ncbi [Epidemiological study of the GEICAM group about breast cancer in Spain (1990-1993): El Alamo project]
    Miguel Martin
    Servicio de Oncologia Medica, Hospital Universitario San Carlos, Madrid, Spain
    Med Clin (Barc) 122:12-7. 2004
    ....
  16. ncbi Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status
    Matthew J Ellis
    Duke University Comprehensive Cancer Center, Campus Box 8056, 660 South Euclid, Durham, NC 27710, USA
    Cancer Res 63:6523-31. 2003
    ....